Irish NCPE rejects funding for Friedreich’s ataxia treatment due to cost-benefit analysis

The National Centre for Pharmacoeconomics (NCPE) has advised against public funding for a Friedreich’s ataxia drug, citing excessive costs relative to clinical efficacy. While the drug is recognized as the current best available option, the decision highlights the ongoing tension between high-cost orphan drug pricing and national health budget sustainability.